OBJECTIVES: This study aims to assess the cost-effectiveness of integrating genomic profiling for determining Homologous Recombination Deficiency (HRD) status in advanced ovarian cancer into the current clinical practice in Greece.

METHODS: A comprehensive cost-effectiveness analysis was conducted to evaluate the integration of genomic profiling into the clinical practice for platinum-sensitive patients with advanced ovarian cancer in Greece, compared to the current standard of care. A decision-analytic model was developed to compare the costs, clinical outcomes, and cost-effectiveness of the two strategies. Data on costs, clinical parameters, utilities and resource utilization were obtained from relevant literature sources. The primary outcome was measured in terms of cost per quality-adjusted progression-free survival (QA-PFS). Additionally, a scenario analysis was performed to estimate the cost per quality-adjusted life year (QALY), providing further insights into the economic implications of the intervention. Discounting was applied to both costs and outcomes using a discount rate of 3% per annum.

RESULTS: The utilization of genomic profiling testing was associated with an additional cost of €28,417 and to an increase of 0.608 in quality-adjusted progression-free survival (QA-PFS), resulting in a incremental cost-effectiveness ratio (ICER) of €46,736 per QA-PFS. Furthermore, the cost per QALY was estimated to be €28,138, indicating that the intervention is cost-effective. Sensitivity analysis demonstrated the robustness of the main findings.

CONCLUSIONS: The integration of genomic profiling for determining HRD status in ovarian cancer is deemed cost-effective and can result in long-term savings. These findings support the implementation of this strategy as part of the standard clinical practice in Greece.